Be on Top of the Latest Happenings: Special Research on La Jolla, Lpath, Macrocure, Momenta, and NanoString
NEW YORK, February 17, 2015 /PRNewswire/ --
Editor Note: For more information about this release, please scroll to bottom.
Moments ago, Analysts Review released new research updates concerning several important developing situations including La Jolla (NASDAQ: LJPC), Lpath (NASDAQ: LPTN), Macrocure (NASDAQ: MCUR), Momenta (NASDAQ: MNTA), and NanoString (NASDAQ: NSTG). Analysts Review provides a single unified platform for investors' to hear about what matters - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.
To access our full PDF reports on a complementary basis, please visit the links below.
--
Today's update concerns the following companies:
============
Full PDF Download Links (you may have to copy and paste the following links into your browser):
LJPC Research Report: ( http://get.analystsreview.com/pdf/?c=La%20Jolla&d=17-Feb-2015&s=LJPC ),
LPTN Research Report: ( http://get.analystsreview.com/pdf/?c=Lpath&d=17-Feb-2015&s=LPTN ),
MCUR Research Report: ( http://get.analystsreview.com/pdf/?c=Macrocure&d=17-Feb-2015&s=MCUR ),
MNTA Research Report: ( http://get.analystsreview.com/pdf/?c=Momenta&d=17-Feb-2015&s=MNTA ),
NSTG Research Report: ( http://get.analystsreview.com/pdf/?c=NanoString&d=17-Feb-2015&s=NSTG ).
============
--
Analyst Update: Agreements, Submission of New Drug Application, Appointments, Upcoming Earnings, and Preliminary Financial Results
Reviewed by: Rohit Tuli, CFA®
The majority of the European markets closed lower on Monday, February 16, ahead of an announcement from the meeting of Eurozone finance ministers in Brussels. However, their discussion over a new financing arrangement for Greece broke down abruptly, showing a wide gap between Athens and its official creditors while also triggering a period of heightened uncertainty about Greece's future inside the currency bloc. The discussion ended after Greece rejected an extension of its current 240-billion-euro ($272 billion) bailout program under the conditions being offered by other ministers. The Euro Stoxx 50 decreased by 0.41 % to 3,433.30, the CAC 40 fell by 0.16 % to 4751.95 and the FTSE 100 was down by 0.24 % to 6857.05. However, the Asian markets ended higher on Monday. Japanese shares rallied to an eight-year high on Monday, on Greece deal hopes and after official data confirmed that Japan's economy pulled out of recession in the last quarter of last year. Chinese market also closed higher, after official data showed that China's foreign direct investment surged in January. US markets were closed on Monday on account of President's Day.
La Jolla Pharmaceutical Company (La Jolla) has reached agreement with the U.S. Food and Drug Administration (FDA) on a Special Protocol Assesment (SPA) for its Phase 3 clinical trial of LJPC-501 for the treatment of catecholamine-resistant hypotension (CRH).
Lpath, Inc. (Lpath) has submitted an Investigational New Drug (IND) application to the United States Food and Drug Administration (FDA) to conduct a Phase 1 study of Lpathomab™ for the treatment of neuropathic pain. Lpath plans to begin enrolling patients once the FDA's IND review period is complete. The study has been approved by the trial sites' investigational review boards.
Macrocure Ltd. (Macrocure) has appointed Mark Page, a Managing Director at Credit Suisse as the Company's CFO, effective February 10, 2015. In his role at Credit Suisse's Global Healthcare Investment Banking Group, Mark led the firm's medical device franchise since 2010 and was involved in some of the industry's most recognized transactions, including the pending purchase of Biomet by Zimmer, amongst others.
Momenta Pharmaceuticals, Inc. (Momenta) to release its Q4 and full year 2014 financial results on Tuesday, February 17, 2015, before the U.S. financial markets opens. Followed by the earnings release, its management will host a conference call to discuss the results and provide an update on the Company on the same day at 10:00 a.m. EST.
NanoString Technologies, Inc. (NanoString) provided an update on operational and preliminary financial results for 2014, wherein it highlighted that it expects total revenue for the year to be in the range of $47.0 million to $48.0 million, representing an increase of 50% to 53% YoY.
--
About Analysts Review
At Analysts Review, we provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Analysts Review comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.
Analysts Review was designed for investors. By providing the best information available, we have set ourselves apart as one of the premier online investor communities.
--
Editor Note: This is not company news. We are an independent source and our views do not reflect the companies mentioned.
Compliance Procedure: Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA®. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
Further Resources: For more information about this release including editorial notes, compliance procedures and legal disclosures, please visit: http://www.analystsreview.com/editors
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts Review
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article